Drug Profile
AUTO 6
Alternative Names: Anti-GD2 chimeric antigen receptor T-cell therapy - Autolus; AUTO6; T-cell replacement therapy- AutolusLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator University College London
- Developer Autolus
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Neuroblastoma
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for phase-I development in Neuroblastoma(Combination therapy, In adolescents, In children, In the elderly, In infants, Second-line therapy or greater, In adults) in United Kingdom (IV, Infusion)
- 28 Oct 2021 No recent reports of development identified for phase-I development in Neuroblastoma(In adolescents, In children, In the elderly, In infants, Monotherapy, Second-line therapy or greater, In adults) in United Kingdom (IV, Infusion)
- 30 Nov 2020 Adverse events and therapeutics data from a phase I trial in Neuroblastoma released by Autolus Therapeutics